Aaron Goodman: I have strong opinions on FLT3i maintenance post allogeneic transplant
Aaron Goodman shared a post by Wolver Heme on X/Twitter:
“I have strong opinions on FLT3i maintenance post allogeneic transplant. Basically, we just put a patient through the most intensive therapy possible (induction chemotherapy followed by an allogeneic transplant). I will not prescribe maintenance unless I am given solid data on Overall Survival advantage.”
Quoting Wolver Heme‘s post:
“The newest episode is out! ‘AML Maintenance Part 2: a metaMORPHOsis?‘ Anthony Perissinotti and Bernie Marini tackle the tough topic of FLT3i maintenance therapy!”
For the episode click here.
Source: Aaron Goodman/Twitter and Wolver Heme/Twitter
Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023